Kajian klinikal COPD di Georgia
12 kajian untuk COPD sedang mencari peserta di lokasi di Georgia.
Bandar di Georgia
Teks kajian rasmi (Bahasa Inggeris)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
Mengambil pesertaFasa 2
Umur 40 hingga 85 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07684820Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07190209A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
Mengambil pesertaFasa 4
Umur 40 hingga 85 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07053423A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
Mengambil pesertaFasa 2/3
Umur 35 hingga 80 · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT07363694eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
Mengambil pesertaFasa 3
Umur 40 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
Mengambil pesertaFasa 2
Umur 35 hingga 89 · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- dan 1 lagi
Mengambil pesertaFasa 3
Umur 40 hingga 80 · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
Mengambil pesertaKajian pemerhatian
Umur 50 ke atas · Semua jantina · Dikemas kini 5 Ogo 2025 · NCT06122077Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.